Hypertension and hyperuricemy

Česká verzia

Authors: J. Špinar ¹; J. Vítovec ²; J. Pařenica ¹
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ²
Published in the journal: Vnitř Lék 2005; 51(1): 82-86
Category: Reviews

Summary

The authors give an overview of contemporary knowledge of the importance of plasma uricacid level in hypertension. Uric acid level is an independent prognostic factor in hypertension, ischemic heart disease and chronic heart failure. Uric acid level increase is very often accompanied by renal insufficiency. Nowadays it is recommended to influence uric acid level by dietary measures and correct choice of antihypertensive drug. Thiazid diuretics are inappropriate, losartan, ACE inhibitors and calcium channels blockers are recommended. Uricosuric and uricostatic drugs are recommended in overt gout and gouty nephropathy. Their preventive administration has not been examined, however, the authors recommend to administer allopurinol in uric acid > 600 μmol/l.

Key words:
uric acid level – hypertension – ischemic heart disease – chronic heart disease – uricosuric drugs – allopurinol

Zdroje

1. Alderman MH, Kivlingh S, Beauchard L et al. Increased serum acid associated with increased cardiovascular disease in treated hypertensive patients. J Hypertens 1998; 16: S5 (abstract).

2. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during twenty years of successful antihypertensive treatment. J Hypertens 1998; 16: 761–769.

3. Anker SD, Doehner W, Rauchhaus M et al. Uric Acid and Survival in Chronic Heart Failure. Circulation 2003; 107: 1991–1997.

4. Bengtson C. Elevated serum uric acid levels during treatment with antihypertensive drugs. Acta Med Scand 1979; 628: 69–71.

5. Bevers DG, Lip GYH. Is uric acid really an indipendent cardiovascular risk factor. Lancet 1998; 352: 1556.

6. Brown MJ, Palmer CR, Cystaigne A et al. Morbidity and mortality in patients randomised to double blind treatment with long acting calcium channel blocker or diuretics in the International Nifedipine GITS study (INSIGHT): International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment. Lancet 2000; 356: 366–372 .

7. Burnier M, Brunner HR. Renal effects of angiotensin II receptor and angiotensin- converting inhibition in healthy subjects. Exp Nephrol 1996, (Supl) 1: 41–46.

8. Conen D, Wietlisbach V, Bovet P et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004; 4 (1): 9.

9. Dahlof B, Devereux RB, Kjeldsen SE. for the LIFE investigators: Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

10. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2846–2497.

11. Franse LV, Pahor M, Di Bari M et al. Serum uric acid, its change with diuretic use and risk of cardiovascular events in the Systolic Hypertension Elderly Program (SHEP). Ústní sdělení AHA, NY, USA 1999.

12. Freedman DS, Williamson F, Gunter EW et al. Relation of serum uric acid to mortality and ischemic heart disease. Am J Epidemiol 1995; 141: 637–644.

13. Frohlich ED. Uric acid: A risk factor for coronary heart disease. JAMA 1993; 270: 354–359.

14. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421–1431.

15. Hare JM, Johnson RJ. Uric Acid predicts Clinical Outcomes in Heart Failure. Circulation 2003; 107: 1951–1953.

16. Chobanian AV. JNC 7 Express. NIH publication 2003; 03–5233: 1–52.

17. Kaplan NM. Diuretics: Cornerstone of antihypertensive therapy. Am J Cardiol 1996; 77: 3B–5B.

18. Kroužecký A, Matějovič M, Rokyta R et al. Rabdomyolýza – mechanismy vzniku, příčiny, důsledky a léčba. Vnitř Lék 2003; 8: 668–672.

19. Levine W, Dyer AR, Shekelle RB et al. Serum uric acid and 11,5 year mortality of middle-aged women. Findings from the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989; 42: 257–267.

20. Messerli FH, Frohlich ED, Dreslinski ER et al. Serum uric acid in essential hypertension. An indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817–827.

21. Pařenica J, Kubecová L, Špinar J et al. Ambulantní monitorování krevního tlaku u mladé populace. Vnitř Lék 2001; 47 (12): 856–862.

22. Reaven G. Metabolic syndrom. Circulation 2002; 106: 286–288.

23. Růžička V. Dna. Interní medicína pro praxi 2003; 4: 172–176.

24. Saaveda WF, Paolocci A, St.John ME et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in failing heart. Circ Res 2002; 90: 297–304.

25. Spieker LE, Ruschitzka FT, Lusher TF et al. The management of hyperuricemia and gout in patients with heart failure. Eur J. Heart Failure 2002; 4: 403–410.

26. Staessen J. The determinants and Prognostic Significance of Serum Uric Acid in Elderly Patients of the European Working Party on High Blood pressure in the Elderly Trial. Am J Medicine 1991; 90: 50–54.

27. Stanton JR, Freis, ED. Serum uric acid concentration in essential hypertension. Proc Soc Exp Biol Med 1947; 66: 193–194.

28. Struthers AD, Donnan PT, Lindsay P et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 3: 229–234.

29. Špinar J, Vítovec J. AII antagonisté vytáhli trumfové eso – studie LIFE a SCOPE. Cor Vasa 2002; 44 (12): 537–541.

30. Špinar J, Vítovec J. Ischemická choroba srdeční. Praha: Grada 2003.

31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack

Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

32. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-contolled, multicentre trial (the EUROPA study). Lancet 2003; 362:782–788.

33. The HOPE investigators: Effects of angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. NEJM 2000; 342: 145–153.

34. The STOP Hypertension 2 Investigators: Swedish Trial in Old Patients with Hypertension 2. Lancet 1999; 354: 1751–1756.

35. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. Praha: Grada 2000.

36. Zanchetti A. for the guidelines committee: 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011–1023.